SEARCH

SEARCH BY CITATION

  • 1
    Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004; 50: 378391.
  • 2
    Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 8348.
  • 3
    Bresnihan B, Baeten D, Firestein GS, FitzGerald OM, Gerlag DM, Haringman JJ, et al. Synovial tissue analysis in clinical trials. J Rheumatol 2005; 32: 24814.
  • 4
    Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, Van den Bosch F, Bresnihan B, et al. A randomized controlled trial with an anti-CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 238792.
  • 5
    Vergunst CE, Gerlag DM, Dinant HJ, Smeets TJ, Reedquist KA, Tak PP. Results of a double-blind, placebo-controlled proof of principle trial with an orally administered C5a-receptor antagonist in patients with active RA. Rheumatology (Oxford). In press.
  • 6
    Mojcik CF, Kremer J, Bingham C, Burch F, Vitiello S, McCroskery E. Results of a phase 2b study of the humanized anti-C5 antibody eculizumab in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2004; 63(Suppl 1): 301.
  • 7
    Gerlag D, Tak PP. Synovial biopsy. Best Pract Res Clin Rheumatol 2005; 19: 387400.
  • 8
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 9
    Smeets TJ, Kraan MC, Versendaal J, Breedveld FC, Tak PP. Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo. J Rheumatol 1999; 26: 208993.
  • 10
    Baeten D, Houbiers J, Kruithof E, Vandooren B, Van den Bosch F, Boots AM, et al. Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 9907.
  • 11
    Bresnihan B, Gerlag DM, Rooney T, Smeets TJ, Wijbrandts CA, Boyle D, et al. Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. J Rheumatol 2007; 34: 6202.
  • 12
    Thurlings RM, Vos K, Wijbrandts CA, Gerlag DM, Tak PP. Dynamics of the synovial B cell response to rituximab therapy in rheumatoid arthritis: evaluation of serial synovial biopsies during the first four months of treatment [abstract]. Presented at the Congress of the European League Against Rheumatism. 2007 June 13–16; Barcelona, Spain.